Washington, DC 20006-5349
HELPLINE
In this episode of MesoTV, Julie sits down with Dr. Raffit Hassan and Dr. David Schrump from the Center for Cancer Research at National Institutes of Health and National Cancer Institute to discuss BAP1 and how it relates to mesothelioma.BAP1 stands for BRCA1-associated protein 1. It’s a gene that makes…
This session from our 2025 International Symposium on Malignant Mesothelioma was filmed on October 25th in Philadelphia, Pennsylvania. Santhosshi Narayanan, MD, FACP from MD Anderson Cancer Center, presents on Integrative Medicine.This presentation explores the role of integrative medicine in supporting mesothelioma patients and their families throughout diagnosis, treatment, and recovery.…
Dear Members of the Meso Community, We understand the deep concern many of you are feeling regarding the current changes and fluctuations in funding for federal programs. The mesothelioma community is tied into federal programming in a few ways, but the two main ones are: Patient services, clinical trials, and research through…
On this episode of MesoTV, our Patients Services Director, Julie White, RN, BSN, OCN, sits down with our new Executive Director, Brian Lepacek, MDiv, CAE, to discuss his role and how he got to the foundation. If you haven’t met Brian yet, definitely check out this episode to get to…
CAR-T (Chimeric antigen receptor) cell therapy is a type of immunotherapy that uses a patient’s T cells to attack cancer cells. T cells are white blood cells that fight infection and illness, but cancer cells can sometimes trick the immune system. CAR T-cell therapy helps the body’s immune system see…
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with pemetrexed and platinum-based chemotherapy. Keytruda(pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help…
Mesothelioma has often been classified as a cancer that only affects older people, as the average age of diagnosis for pleural is 72 and peritoneal is 67. This assumption of advanced age being a factor has led to misdiagnosis among younger patients. The demographic of meso patients is consistently changing…
The Mesothelioma Applied Research Foundation is excited to announce its latest research grant recipients, awarding a total of $300,000. This brings the Foundation’s…
One of the many services that the Meso Foundation offers to patients, caregivers, and the bereaved community is support groups offered over Zoom video conferencing.…
UPDATE: Deadline extended to November 17 at 11:59 PM ET. Thanks to the generous support of our patients, families, caregivers, corporate supporters, and the many…
